Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties

被引:36
|
作者
Nakayama, Mizuho [1 ,2 ]
Hong, Chang Pyo [3 ]
Oshima, Hiroko [1 ,2 ]
Sakai, Eri [1 ]
Kim, Seong-Jin [3 ,4 ,5 ]
Oshima, Masanobu [1 ,2 ]
机构
[1] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan
[2] Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, Japan
[3] Theragen Etex Bio Inst, Suwon 16229, South Korea
[4] Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, South Korea
[5] Seoul Natl Univ, Dept Transdisciplinary Studies, Suwon 16229, South Korea
关键词
DRIVES METASTASIS; CANCER; GAIN; GENE; COMPLEX; CELLS; PATTERNS; MUTATION; GROWTH;
D O I
10.1038/s41467-020-16245-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Missense-type mutant p53 plays a tumor-promoting role through gain-of-function (GOF) mechanism. In addition, the loss of wild-type TP53 through loss of heterozygosity (LOH) is widely found in cancer cells. However, malignant progression induced by cooperation of TP53 GOF mutation and LOH remains poorly understood. Here, we show that mouse intestinal tumors carrying Trp53 GOF mutation with LOH (AKTP(M/LOH)) are enriched in metastatic lesions when heterozygous Trp53 mutant cells (AKTP(+/M)) are transplanted. We show that Trp53 LOH is required for dormant cell survival and clonal expansion of cancer cells. Moreover, AKTP(M/LOH) cells show an increased in vivo tumor-initiating ability compared with AKTP(Null) and AKTP(+/M) cells. RNAseq analyses reveal that inflammatory and growth factor/MAPK pathways are specifically activated in AKTP(M/LOH) cells, while the stem cell signature is upregulated in both AKTP(M/LOH) and AKTP(Null) cells. These results indicate that TP53/Trp53 LOH promotes TP53/Trp53 GOF mutation-driven metastasis through the activation of distinct pathway combination. Both gain-of-function of mutant p53 (GOF) and loss of wild-type p53 (LOH) are independently associated with cancer. Here, the authors show that LOH promotes GOF tumourigenesis by increasing tumor-initiating ability and metastasis.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
    Bollu, Lakshmi Reddy
    Shepherd, Jonathan
    Zhao, Dekuang
    Ma, Yanxia
    Tahaney, William
    Speers, Corey
    Mazumdar, Abhijit
    Mills, Gordon B.
    Brown, Powel H.
    NPJ BREAST CANCER, 2020, 6 (01)
  • [22] p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form
    Sengupta, Shinjinee
    Singh, Namrata
    Paul, Ajoy
    Datta, Debalina
    Chatterjee, Debdeep
    Mukherjee, Semanti
    Gadhe, Laxmikant
    Devi, Jyoti
    Mahesh, Yeshwanth
    Jolly, Mohit Kumar
    Maji, Samir K.
    JOURNAL OF CELL SCIENCE, 2023, 136 (17)
  • [23] MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53
    Fukaya, Raita
    Ohta, Shigeki
    Yaguchi, Tomonori
    Matsuzaki, Yumi
    Sugihara, Eiji
    Okano, Hideyuki
    Saya, Hideyuki
    Kawakami, Yutaka
    Kawase, Takeshi
    Yoshida, Kazunari
    Toda, Masahiro
    CANCER RESEARCH, 2016, 76 (09) : 2813 - 2823
  • [24] Berberine Inhibits Cell Proliferation by Interfering with Wild-Type and Mutant P53 in Human Glioma Cells
    Liu, Ziqiang
    Chen, Yong
    Gao, Haijun
    Xu, Weidong
    Zhang, Chaochao
    Lai, Jiacheng
    Liu, Xingxing
    Sun, Yuxue
    Huang, Haiyan
    ONCOTARGETS AND THERAPY, 2020, 13 : 12151 - 12162
  • [25] Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery
    Kamath, Divya
    Iwakuma, Tomoo
    Bossmann, Stefan H.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2024, 56
  • [26] RITA has growth inhibitory activity on colon cancer HCT116 cells expressing wild-type p53, but not SW480 cells harboring mutant p53, via repressing wild-type p53 ubiquitination
    Yu, Xingquan
    Han, Bing
    Guo, Song
    Hu, Baoguang
    Pan, Xiangpo
    Li, Hesheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (09): : 17569 - 17578
  • [27] p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53
    Zhou, Yao
    Niu, Weihong
    Luo, Yanwei
    Li, Hui
    Xie, Yong
    Wang, Heran
    Liu, Yukun
    Fan, Songqing
    Li, Zheng
    Xiong, Wei
    Li, Xiaoling
    Ren, Caiping
    Tan, Ming
    Li, Guiyuan
    Zhou, Ming
    CANCER SCIENCE, 2019, 110 (03) : 939 - 949
  • [28] Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53
    York, D.
    Withers, S. S.
    Watson, K. D.
    Seo, K. W.
    Rebhun, R. B.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2017, 15 (03) : 1087 - 1100
  • [29] Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53
    Xu, Dandan
    Tong, Xin
    Sun, Leyu
    Li, Haonan
    Jones, Ryan D.
    Liao, Jie
    Yang, Guang-Yu
    MOLECULAR CARCINOGENESIS, 2019, 58 (11) : 2052 - 2064
  • [30] Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
    Butturini, Elena
    Butera, Giovanna
    Pacchiana, Raffaella
    de Prati, Alessandra Carcereri
    Mariotto, Sofia
    Donadelli, Massimo
    CELLS, 2021, 10 (11)